Lilly Previews Retatrutide and Foundayo at ADA 2026
Lilly will present pivotal Phase 3 retatrutide data and new Foundayo results at the ADA's 86th Scientific Sessions in New Orleans, June 5–8, 2026.
May 29, 2026 · 2 min read
Eli Lilly announced it will present new data on retatrutide, Foundayo, and Mounjaro at the American Diabetes Association's 86th Scientific Sessions in New Orleans, running June 5–8, 2026. The presentations include pivotal Phase 3 TRIUMPH results for retatrutide and data on Foundayo, Lilly's oral GLP-1 that the company has described as the only approved oral GLP-1 taken without food or water restrictions.
What's being presented
A dedicated retatrutide symposium is scheduled for Saturday, June 6, 2026, from 1:30–3:00 p.m. CDT. The session will feature Phase 3 results from the TRIUMPH clinical trial program, including data beyond the topline TRIUMPH-1 results the company reported in May.
The ADA sessions arrive one week after the TRIUMPH-1 topline announcement, and the full scientific presentations typically include more granular data than press releases: responder analyses, body composition changes, detailed safety tables, and secondary endpoint results. Clinicians and researchers will be watching for subgroup data on older adults, people with type 2 diabetes, and the safety profile at the 9 mg versus 12 mg doses where GI tolerability questions have been raised.
Lilly will also present data on Foundayo, the brand name for orforglipron in its approved indication. Foundayo is an oral small-molecule GLP-1 receptor agonist. Unlike oral semaglutide (Rybelsus), which requires a fasting window and specific water restriction for absorption, Foundayo does not carry those dietary constraints — a practical advantage for patients who struggle with the Rybelsus regimen.
Why this matters for the pipeline
The ADA Scientific Sessions are one of the highest-profile annual venues for metabolic medicine. Lilly presenting TRIUMPH data there — alongside Mounjaro — signals that the company is moving toward full regulatory dossier readiness for retatrutide. Peer-reviewed publication of the Phase 3 data (typically needed for FDA NDA submission) often follows or accompanies major congress presentations.
For Foundayo, ADA 2026 data will likely shape clinical decision-making about where an oral non-semaglutide GLP-1 fits in the T2D and weight management landscape. A drug that can be taken without food restrictions addresses a real compliance barrier and opens the pathway for patients who can't or won't self-inject.
The Mounjaro presentations are expected to include SURMOUNT extension data and real-world effectiveness analyses, building the body of evidence for tirzepatide's long-term profile.
What to watch
Coverage from ADA 2026 will be dense. The retatrutide symposium on June 6 is the headline session, but data on drug combinations, pediatric studies, and cardiovascular outcomes in the TRIUMPH program will likely appear in multiple poster and oral sessions across the four days. Watch for journal publication announcements accompanying the congress data — NEJM and Lancet often accept major trial data for publication coinciding with congress presentations.
For background on retatrutide's clinical profile, see our retatrutide cardiovascular outcomes overview and should I wait for retatrutide guide.
Sources
Sources